Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 complex as a serum biomarker for COVID-19 [PDF]
Frontiers in Immunology, 2023 Patients with coronavirus disease-2019 (COVID-19) have an increased risk of thrombosis and acute respiratory distress syndrome (ARDS). Thrombosis is often attributed to increases in plasminogen activator inhibitor-1 (PAI-1) and a shut-down of ...
Tetiana Yatsenko +12 more
doaj +2 more sources
Urokinase-type plasminogen activator blockade ameliorates experimental colitis in mice [PDF]
Scientific Reports, 2023 Although several angiogenesis-related factors are reportedly involved in the pathogenesis of ulcerative colitis (UC), the mechanisms by which they contribute to disease are unclear.
Yoshifumi Kida +13 more
doaj +2 more sources
A “turn-off” photoacoustic contrast for urokinase-type plasminogen activator activity [PDF]
npj Biomedical InnovationsThe ability to distinguish cancerous lesions based on aggressiveness using noninvasive molecular imaging techniques enables more precise and accurate diagnosis.
Ananya Sharma +4 more
doaj +2 more sources
Amiloride selectively inhibits the urokinase‐type plasminogen activator
FEBS Letters, 1987 The diuretic drug amiloride, an inhibitor of Na+ uptake, competitively inhibits the catalytic activity of the urokinase‐type plasminogen activator (u‐PA), with a K i of 7 × 10−6 M. Generation of plasmin, cleavage of peptide substrates, and interaction of u‐PA with a specific macromolecular proteinase inhibitor are all prevented in the presence of the ...
J D Vassalli, D Belin
exaly +4 more sources
Urokinase-Type Plasminogen Activator Receptor (uPAR) in Inflammation and Disease: A Unique Inflammatory Pathway Activator [PDF]
BiomedicinesThe urokinase-type plasminogen activator receptor (uPAR) is a unique protease binding receptor, now recognized as a key regulator of inflammation.
Mostafa Hamada +9 more
doaj +2 more sources
Medical Journal of Babylon, 2023 Background: Type 2 diabetes mellitus is a progressive and chronic disease manifested by β-cell dysfunction and improved insulin resistance. Higher levels of urokinase-type plasminogen activator receptors have been found to predict morbidity and mortality
Melak Saleh Mohammed, Hind Shakir Ahmed
doaj +1 more source
Corrigendum: Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 complex as a serum biomarker for COVID-19 [PDF]
Frontiers in ImmunologyTetiana Yatsenko +12 more
doaj +2 more sources
The uPA System Differentially Alters Fibroblast Fate and Profibrotic Ability in Skin Fibrosis
Frontiers in Immunology, 2022 Skin fibrosis is a common pathological feature of various diseases, and few treatment strategies are available because of the molecular pathogenesis is poorly understood.
Ming-Li Zou +15 more
doaj +1 more source
Romanian Journal of Laboratory Medicine, 2021 Background: To explore the values of serum procalcitonin (PCT), soluble urokinase-type plasminogen activator receptor (suPAR) combined with APACHE II and SOFA scores for evaluating the prognosis of septic shock patients.
Wang Wenxin, Jie Yingxin, Zhou Jia
doaj +1 more source
Urokinase‐Type Plasminogen Activator, an Endogenous Antibiotic [PDF]
The Journal of Infectious Diseases, 2005 Urokinase-type plasminogen activator (uPA) is a serine protease that not only displays fibrinolytic function but also modulates innate and adaptive immune responses. In the present study, we assessed whether uPA acts as an endogenous antibiotic. It has been demonstrated that uPA inhibits growth of Staphylococcus aureus both in vivo and in vitro ...
Tao, Jin +2 more
openaire +2 more sources